Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies

Ehsan Rahimy, MD; David G. Miller, MD, and Jordana Fein, MD, discusses how 8 milligram aflibercept and faricimab, newer anti-VEGF therapies for retinal diseases, offer improved durability with comparable safety profiles to existing treatments, allowing less frequent injections while maintaining equivalent vision outcomes.

Related Content:

Optimizing nAMD and DME Treatment: Real-World Durability, and Fluid Outcomes with Second Generation Anti-VEGF AgentsClinicalVideo Series

Study Finds Diagnostic Delay, Less Intensive Therapy Use in PsA than RA

Gaps in Knowledge Identified Regarding Skin Health Outcomes in Migrant Populations

High Costs, Shortages Stand as Barriers for Obtaining Epinephrine Autoinjectors